Navigation Links
Proteins do not predict outcome of herceptin treatment in HER2-positive breast cancer
Date:12/8/2011

SAN ANTONIO -- Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer with Herceptin, say Mayo Clinic researchers. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth.

The finding, presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, represents a disappointment to oncologists who had hoped to find distinct biomarkers beyond standard HER2 testing that could help them gauge how well Herceptin will work for patients.

"This study debunks the hopeful notion, strongly felt in the breast cancer community, that measuring levels of a number of different proteins in the HER2 family could help oncologists better tailor their use of Herceptin," says the study's senior investigator, Edith Perez, M.D., director of Mayo Clinic's Breast Program in Florida.

"Improving our ability to predict the benefit of Herceptin treatment beyond testing for HER2 protein and genes remains an important goal, but we are not there yet," she says.

Currently, patients are considered eligible for Herceptin if a pathologist estimates that at least 10 percent of their tumor samples test positive for HER2 growth proteins. However, the test is relatively subjective, based on a HER2 stain on a slide of tumor tissue. While the test can predict the outcome of Herceptin treatment, which shuts down the HER2 growth receptor for some patients, it cannot do so for all patients, Dr. Perez says.

Researchers used a tool that precisely measures the amount of a protein expressed in a cancer sample. According to Dr. Perez, this study was the first to meticulously measure protein levels, including HER2, HER3, HER4, EGFR (epidermal growth factor receptor), ER (estrogen receptor), and PTEN (a tumor suppressor gene) in almost 1,400 tumor biopsies.

Many researchers thought that analysis of the HER3 protein might be a good predictive marker because HER2 and HER3 interact together to promote cancer growth, Dr. Perez says.

"A biopsy could have 80 percent HER3 protein, and it wouldn't be any different in terms of a patient's outcome from Herceptin use than a tumor that had 5 percent HER3 protein," she says.

The next step to finding predictive biomarkers showing a benefit to Herceptin use will be to look at multi-gene profiles, not single biomarkers, Dr. Perez says.


'/>"/>

Contact: Joe Dangor
dangor.yusuf@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Linking Fragile X Syndrome proteins and RNA editing mistakes at nerve-muscle junction
2. Blood proteins predict survival in idiopathic pulmonary fibrosis, Pitt-led team says
3. Researchers find coupling of proteins promotes glioblastoma development
4. Researchers identify enzyme that regulates degradation of damaged proteins
5. Proteins could help women avoid thyroid surgery
6. Small Study Suggests Milk, Soy Proteins Lower Blood Pressure Modestly
7. Proteins used to map the aging process
8. Deadly bacteria may mimic human proteins to evolve antibiotic resistance
9. NIH scientists identify most proteins made by parasitic worm
10. Cell rigidity linked to activity in proteins associated with cancer
11. 2 defective proteins conspire to impair the nerve cells powerhouse in Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
(Date:10/7/2017)... 2017   Provista, a proven leader in ... in purchasing power, today announced a new resource area ... Newsroom is the online home for case studies, ... bios, news releases, slideshows and events. ... of resources at their fingertips, viewers can also watch ...
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
Breaking Medicine Technology: